Related Experiment Video

Updated: Feb 4, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Qi Shen1, Jun Li1,2, Junhua Mai1

  • 1Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA.

Cell Death & Disease
|September 26, 2018
PubMed

Insights

Targeting non-small cell lung cancer (NSCLC) requires understanding protein expression. This study reveals that MCL-1 levels dictate sensitivity to BCL-2 inhibitors, suggesting a personalized treatment approach for lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer death.
  • Apoptosis regulators, like BCL-2 family proteins, are crucial in cancer development.
  • Understanding protein expression profiles can stratify NSCLC patients for targeted therapies.

Purpose of the Study:

  • To investigate the role of MCL-1 expression in NSCLC sensitivity to BCL-2/BCL-xL/BCL-w inhibitor ABT-263 (navitoclax).
  • To explore combination strategies involving ABT-263 and MCL-1 suppression or chemotherapy.
  • To establish a rationale for molecular profiling in NSCLC treatment.

Main Methods:

  • Analysis of pro-apoptotic and anti-apoptotic protein expression in NSCLC.
  • Treatment of NSCLC cells with ABT-263 alone and in combination with MCL-1 siRNA.
  • Assessment of apoptosis induction and mitochondrial priming levels.
  • Combination treatment with docetaxel and ABT-263 in low MCL-1 expressing cells.

Main Results:

  • NSCLC cells were categorized into two groups based on protein expression profiles.
  • ABT-263 monotherapy did not induce apoptosis in either group.
  • Moderate to high MCL-1 expression predicted sensitivity to ABT-263 combined with MCL-1 siRNA.
  • Low MCL-1 expression correlated with low mitochondrial priming, which was reversed by docetaxel, sensitizing cells to ABT-263.

Conclusions:

  • MCL-1 expression levels are critical determinants of NSCLC response to BCL-2 family inhibitors.
  • Combining MCL-1 suppression or chemotherapy with ABT-263 can overcome resistance in specific NSCLC subtypes.
  • Molecular profiling of MCL-1 expression offers a strategy for personalized anti-cancer drug selection in NSCLC.

More Related Videos

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.4K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
15.1K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K